Casi PharmaceuticalsCASIF
13F holders, Q1 2024 (March 31)20holders
1famous investor
$3.61avg. 13F price*
At the end of Q1 2024, 20 institutions reported holding Casi Pharmaceuticals Inc. (CASIF) in their 13F filings. The largest holders were Wellington Shields Capital Management, LLC ($333K), Wellington Shields & Co., LLC ($156K) and Howland Capital Management LLC ($146K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Casi Pharmaceuticals Inc.
- CUSIP
- G1933S101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $149K |
| Exits | 4 | $336K |
Ownership 20 holders
| Wellington Shields Capital Management, LLC | 0.06% | Reduce -30.7% | 92,217 | $333K |
| Wellington Shields & Co., LLC | 0.05% | No change | 43,091 | $156K |
| Howland Capital Management LLC | 0.01% | New | 40,429 | $146K |
| Renaissance Technologies | 0.00% | Add +26.5% | 36,800 | $133K |
| Geode Capital Management, LLC | 0.00% | No change | 22,221 | $80K |
| Wells Fargo & Company | 0.00% | Add +200000.0% | 12,006 | $43K |
| Catalyst Funds Management Pty Ltd | 0.00% | — | 1,810 | $7K |
| Morgan Stanley | 0.00% | Reduce -1.1% | 1,437 | $5K |
| Simplex Trading, LLC | 0.00% | Add +1075.5% | 623 | $2K |
| FMR LLC | 0.00% | New | 500 | $2K |
| BlackRock Inc. | 0.00% | No change | 296 | $1K |
| TD Waterhouse Canada Inc. | 0.00% | New | 300 | $1K |
| West Paces Advisors Inc. | 0.00% | No change | 100 | $361 |
| Bank of America Corp. | 0.00% | Add +1666.7% | 53 | $191 |
| IFP Advisors, Inc | 0.00% | New | 40 | $144 |
| JPMorgan Chase & Co. | 0.00% | No change | 25 | $90 |
| Mendota Financial Group, LLC | 0.00% | New | 20 | $73 |
| Northwestern Mutual Wealth Management Co. | 0.00% | No change | 13 | $47 |
| Colonial Trust Co / SC | 0.00% | No change | 11 | $40 |
| Kozak & Associates, Inc. | 0.00% | No change | 10 | $32 |
"% of holder's portfolio" is CASIF's weight in each manager's 13F, not the share of Casi Pharmaceuticals Inc. the manager owns.